Country: Singapore
Language: English
Source: HSA (Health Sciences Authority)
(UMEC STRIP) UMECLIDINIUM BROMIDE (MICRONISED) 74.2 mcg/dose EQV UMECLIDINIUM; (VI STRIP) VILANTEROL TRIFENATATE (MICRONISED) 40 mcg/dose EQV VILANTEROL
GLAXOSMITHKLINE PTE LTD
R03AL03
POWDER, METERED
(UMEC STRIP) UMECLIDINIUM BROMIDE (MICRONISED) 74.2 mcg/dose EQV UMECLIDINIUM 62.5 mcg/dose; (VI STRIP) VILANTEROL TRIFENATATE (MICRONISED) 40 mcg/dose EQV VILANTEROL 25 mcg/dose
RESPIRATORY (INHALATION)
Prescription Only
GLAXO OPERATIONS UK LTD (TRADING AS GLAXO WELLCOME OPERATIONS)
ACTIVE
2015-08-28
ANORO ELLIPTA UMECLIDINIUM/VILANTEROL QUALITATIVE AND QUANTITATIVE COMPOSITION A light grey inhaler with a red mouthpiece cover and an integral dose counter. The Ellipta inhaler contains two blister strips, each of which contains a white powder. Each delivered dose (the dose leaving the mouthpiece of the inhaler) contains 55 micrograms umeclidinium (equivalent to 65 micrograms of umeclidinium bromide) and 22 micrograms vilanterol (as trifenatate). This corresponds to a pre-dispensed dose of 62.5 micrograms of umeclidinium (equivalent to 74.2 micrograms umeclidinium bromide) and 25 micrograms vilanterol (as trifenatate). CLINICAL PARTICULARS INDICATIONS _ANORO ELLIPTA _is indicated for maintenance bronchodilator treatment to relieve symptoms associated with chronic obstructive pulmonary disease (COPD). DOSAGE AND ADMINISTRATION Pharmaceutical form: Inhalation powder, pre-dispensed _ANORO ELLIPTA _is for oral inhalation only. _ANORO ELLIPTA _should be administered once daily at the same time each day. ADULTS The recommended and maximum dose is one inhalation of _ANORO ELLIPTA _ 62.5/25 micrograms once daily. CHILDREN Use in patients less than 18 years of age is not relevant given the indication for this product. ELDERLY No dosage adjustment is required in patients over 65 years (see _Pharmacokinetics _ _–_ _ _ _Special Patient Populations_). RENAL IMPAIRMENT No dosage adjustment is required in patients with renal impairment (see _Pharmacokinetics _ _—_ _ Special Patient Populations_). HEPATIC IMPAIRMENT No dosage adjustment is required in patients with mild or moderate hepatic impairment. _ANORO ELLIPTA _has not been studied in patients with severe hepatic impairment (see _Pharmacokinetics _ _—_ _ Special Patient Populations_). CONTRAINDICATIONS _ANORO ELLIPTA _is contraindicated in patients with severe milk-protein allergy, or who have demonstrated hypersensitivity to either umeclidinium, vilanterol or any of the excipients in this product. WARNINGS AND PRECAUTIONS ASTHMA _ANORO ELLIPTA _should not be used i Read the complete document